The Europe drug discovery market is projected to register a CAGR of 6.90% during the forecast period, 2022-2030, and is set to garner around $27278.08 million by 2030.
EUROPE DRUG DISCOVERY MARKET FORECAST 2022-2030
Europe Drug Discovery Market by Drug Type (Small Molecule Drug, Biologic Drug) Market by Service (Chemical Services, Drug Metabolism and Pharmacokinetics Services, Biological Services, Other Pharmaceutical Services) Market by End-users (Pharmaceutical Companies, Contract Research Organizations, Research Institutes, Other End-users) Market by Technology (High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies) by Geography
The Europe drug discovery market is projected to register a CAGR of 6.90% during the forecast period, 2022-2030, and is set to garner around $27278.08 million by 2030.
Several types of cancer and circulatory diseases are evaluated to be the key causes of death in European countries, followed by respiratory diseases. Accordingly, drug discovery and development find increasing growth opportunities in the region.
To know more about this report, request a free sample copy
The Europe drug discovery market growth assessment includes the evaluation of Scandinavia, Spain, the United Kingdom, Germany, Russia, Italy, France, and Rest of Europe. In the United Kingdom, the MHRA (Medicines and Health Products Regulatory Agency) regulates pharmaceuticals approvals. It also regulates the entire drug research process from clinical trial to market authorization and post-market safety monitoring. Also, there has been increased funding for clinical research to supplement new drugs delivery, vaccines, and treatments. In addition, the government allocated the research and development budget to DHSC (Department for Health and Social Care) for the work of the GEL (Genomics England) and NHR (National Institute for Health Research) on their research for enhanced patient outcomes.
In France, the National Agency for the Safety of Medicine and Health Products (ANSM) is the regulatory agency for drugs. Also, company initiatives enable growth opportunities. For instance, Sanofi is set to invest in messenger RNA vaccines development in the country. Whereas Russia is a lucrative clinical trial destination, given its centralized healthcare system and low-cost operations. It ranks sixth for the most planned or ongoing clinical trials.
Also, its foothold in the clinical trials sector has strengthened, with trials increasing from 71 to 797 between 2017 and 2021. The leading therapy domains with planned or ongoing trials with one site in Russia are oncology, infectious diseases, gastrointestinal issues, cardiovascular disease, infectious diseases, and central nervous system disorders.
The segmentation assessment of the Europe drug discovery market includes the analysis of drug type, service, technology, and end-user. The drug type segment is sub-categorized into biologic drug and small molecule drug.
Biologic drug is the fastest-growing drug type. It is produced from living organisms. It entails varied products derived from microorganisms, animals, or humans using biotechnology. Recombinant proteins, tissues, genes, allergens, cells, blood components, blood, and vaccines. Biologics are also produced using recombinant DNA technology. They are also termed biological drugs or biopharmaceuticals.
Whereas small molecule drugs enter cells easily since it has a low molecular weight. They can affect other molecules like proteins, causing cancer cells to die once inside them. They vary from drugs with a large molecular weight that hinders their easy entry into cells. Several targeted therapies are small-molecule drugs. They are organic compounds that impact molecular pathways by targeting essential proteins. They are also developed from leads derived from rational drug design.
Some of the key firms in the Europe drug discovery market include Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG, etc.
Novartis is a multinational group of companies specializing in the marketing, manufacturing, development, and research of a vast range of innovative cost-saving generic medicines and pharmaceuticals. It has two global operating divisions, Sandoz: generic pharmaceuticals and biosimilars, and Innovative Medicines: innovative patent-protected prescription medicines.
Promacta® is a key product of the company, approved in the EU, the US, and other countries to treat ITP (Immune thrombocytopenia).
Report Synopsis:
| Report Scope | Details |
| Market Forecast Years | 2022-2030 |
| Base Year | 2021 |
| Market Historical Years | 2018-2021 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Drug Type, Service, End-User, and Technology |
| Countries Analyzed | Scandinavia, Spain, the United Kingdom, Germany, Russia, Italy, France, and Rest of Europe |
| Companies Analyzed |
Roche AG, Pfizer Inc, Bayer AG, Evotec SE, Agilent Technologies Inc, Icon Plc, AstraZeneca Plc, Charles River Laboratories International Inc, Novartis AG, Merck & Co Inc, Eli Lilly and Company, IQVIA Holdings Inc, Johnson & Johnson, and GlaxoSmithKline Plc |
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- KEY DRIVERS
- GROWING R&D FOR TACKLING SEVERAL DISEASES
- TECHNOLOGICAL ADVANCEMENTS
- KEY RESTRAINTS
- EXTENSIVE TIME-CONSUMING PROCESS
- HIGHLY REGULATED MARKET
- PROJECT FEASIBILITY AND SUCCESS RATE
- KEY DRIVERS
- KEY ANALYTICS
- IMPACT OF COVID-19 ON DRUG DISCOVERY INDUSTRY
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- DRUG DISCOVERY AND DEVELOPMENT PROCESS
- DRUG DISCOVERY AND DEVELOPMENT
- PRECLINICAL RESEARCH
- CLINICAL RESEARCH
- REGULATORY AUTHORITY REVIEW
- POST MARKET SAFETY MONITORING
- REGULATORY FRAMEWORK
- MARKET BY DRUG TYPE
- SMALL MOLECULE DRUG
- BIOLOGIC DRUG
- MARKET BY SERVICE
- CHEMICAL SERVICES
- DRUG METABOLISM AND PHARMACOKINETICS SERVICES
- BIOLOGICAL SERVICES
- OTHER PHARMACEUTICAL SERVICES
- MARKET BY END-USER
- PHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS
- RESEARCH INSTITUTES
- OTHER END-USERS
- MARKET BY TECHNOLOGY
- HIGH THROUGHPUT SCREENING
- SPECTROSCOPY
- COMBINATORIAL CHEMISTRY
- BIOCHIPS
- PHARMACOGENOMICS AND PHARMACOGENETICS
- BIOINFORMATICS
- METABOLOMICS
- NANOTECHNOLOGY
- OTHER TECHNOLOGIES
- GEOGRAPHICAL ANALYSIS
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- RUSSIA
- SPAIN
- SCANDINAVIA
- REST OF EUROPE
- EUROPE
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
- AGILENT TECHNOLOGIES INC
- ASTRAZENECA PLC
- BAYER AG
- CHARLES RIVER LABORATORIES INTERNATIONAL INC
- ELI LILLY AND COMPANY
- EVOTEC SE
- GLAXOSMITHKLINE PLC
- ICON PLC
- IQVIA HOLDINGS INC
- JOHNSON & JOHNSON
- MERCK & CO INC
- NOVARTIS AG
- PFIZER INC
- ROCHE AG
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1:Â MARKET SNAPSHOT – EUROPE DRUG DISCOVERY
TABLE 2:Â REGULATORY FRAMEWORK
TABLE 3:Â EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4:Â EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5:Â EUROPE DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6:Â EUROPE DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7:Â EUROPE DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8:Â EUROPE DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9:Â EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10:Â EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11:Â EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12:Â EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13:Â LEADING PLAYERS OPERATING IN EUROPE DRUG DISCOVERY MARKET
TABLE 14:Â LIST OF MERGERS & ACQUISITIONS
TABLE 15:Â LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16:Â LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17:Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES Â Â Â Â Â Â Â Â Â Â Â Â
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
FIGURE 5: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
FIGURE 6: EUROPE DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
FIGURE 7: EUROPE DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
FIGURE 8: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
FIGURE 9: EUROPE DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 10: EUROPE DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 11: EUROPE DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 12: EUROPE DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 13: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 14: EUROPE DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
FIGURE 15: EUROPE DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
FIGURE 16: EUROPE DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
FIGURE 17: EUROPE DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
FIGURE 18: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
FIGURE 19: EUROPE DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
FIGURE 20: EUROPE DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
FIGURE 21: EUROPE DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
FIGURE 22: EUROPE DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
FIGURE 23: EUROPE DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
FIGURE 24: EUROPE DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
FIGURE 25: EUROPE DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
FIGURE 26: EUROPE DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
FIGURE 27: EUROPE DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
FIGURE 28: EUROPE DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 29: UNITED KINGDOM DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 30: GERMANY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: FRANCE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: ITALY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 33: RUSSIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: SPAIN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 35: SCANDINAVIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: REST OF EUROPE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)Â Â Â Â
- GEOGRAPHICAL ANALYSIS
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- RUSSIA
- SPAIN
- SCANDINAVIA
- REST OF EUROPE
- EUROPE
- MARKET BY DRUG TYPE
- SMALL MOLECULE DRUG
- BIOLOGIC DRUG
- MARKET BY SERVICE
- CHEMICAL SERVICES
- DRUG METABOLISM AND PHARMACOKINETICS SERVICES
- BIOLOGICAL SERVICES
- OTHER PHARMACEUTICAL SERVICES
- MARKET BY END-USER
- PHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS
- RESEARCH INSTITUTES
- OTHER END-USERS
- MARKET BY TECHNOLOGY
- HIGH THROUGHPUT SCREENING
- SPECTROSCOPY
- COMBINATORIAL CHEMISTRY
- BIOCHIPS
- PHARMACOGENOMICS AND PHARMACOGENETICS
- BIOINFORMATICS
- METABOLOMICS
- NANOTECHNOLOGY
- OTHER TECHNOLOGIES
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.